Leadership changeRegulatory filing
What was reported
On October 19, 2026, CRISPR Therapeutics AG (the “Company”) announced the promotion of Andrew J. Silver, currently the Company’s SVP, Finance, to be the Company’s Chief Financial Officer effective immediately. Mr. Silver will also serve as the Company’s principal financial officer and principal accounting officer.U.S. Securities and Exchange Commission (EDGAR) · 8-K: 8-K · Oct 19, 2026 · Open the source ↗
What the evidence supports
CRISPR Therapeutics told the SEC (Form 8-K, Item 5.02) that there was a change involving its directors or officers, or their pay arrangements. The filing gives Oct 19, 2026 as the date of the earliest event reported.
What remains unknown
The reasons for the change beyond those stated, and what it means for the company's strategy or results.
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Form 8-K, Item 5.02 textOn October 19, 2026, CRISPR Therapeutics AG (the “Company”) announced the promotion of Andrew J. Silver, currently the Company’s SVP, Finance, to be the Company’s Chief Financial Officer effective immediately. Mr. Silver will also serve as the Company’s principal financial officer and principal accounting officer.U.S. Securities and Exchange Commission (EDGAR) · 8-K: 8-K · Oct 19, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:54 UTC
CRISPR Therapeutics reports changes involving its directors or officers (Form 8-K, Item 5.02)
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.